18 and older, any sex, with Barrett's Esophagus. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Ki67 Biomarker ExpressionPrimary· Baseline and Week 12
Esophagogastroduodenoscopy (EGD) was performed to enable taking biopsies for assessment of Ki67 expression, a marker of cellular proliferation. Ki67 expression was assessed by immunohistochemistry and calculating the number of Ki67 positive cells per mm\^2 of Barrett's epithelium.
Baseline
Group
Value
95% CI
Treatment
1539
± 514
YF476 Placebo
1556
± 622
Week 12
Group
Value
95% CI
Treatment
1575
± 620.7
YF476 Placebo
1864
± 640.3
Expression of Biomarkers Potentially Associated With Esophageal Adenocarcinoma (EAC)Secondary· Week 12
Blood samples were taken for assay of biomarkers associated with esophageal adenocarcinoma. Changes in biomarker expression were derived from RNA-Sequencing and calculated as log-fold change comparing the treatment group to the placebo group. The nature of how results are derived by RNA-sequencing means summary statistics cannot be generated individually for each arm and a value has not been calculated for each individual participant. Therefore, results are reported as the relative change in biomarker expression in the treatment arm compared to the placebo arm.
CCK2R, Week 12
Group
Value
95% CI
Treatment
-1.19
PTGS2, Week 12
Group
Value
95% CI
Treatment
0.31
DCLK1, Week 12
Group
Value
95% CI
Treatment
-0.34
Abundance of Biomarkers of Gastric Acid SuppressionSecondary· Week 4, Week 6, Week 8, Week 12 and Follow-up (4 weeks after stopping YF476 treatment)
Blood samples were taken to assess the effects of YF476 on fasting serum gastrin, a marker of gastric acid suppression
Week 4
Group
Value
95% CI
Treatment
242.6
± 142.3
YF476 Placebo
43.6
± 9.9
Week 6
Group
Value
95% CI
Treatment
103.3
± 89.9
YF476 Placebo
63.9
± 32.2
Week 8
Group
Value
95% CI
Treatment
234.3
± 156.5
YF476 Placebo
96.4
± 54.2
Week 12
Group
Value
95% CI
Treatment
146.8
± 112.8
YF476 Placebo
49.2
± 20.4
Follow-up
Group
Value
95% CI
Treatment
94.9
± 78.8
YF476 Placebo
64.7
± 37.7
Abundance of Biomarkers of ECL Cell HyperplasiaSecondary· Week 4, Week 6, Week 8, Week 12 and Follow-up (4 weeks after stopping YF476 treatment)
Blood samples were taken to assess the effects of YF476 on fasting plasma CgA, a marker of ECL cell hyperplasia
Week 4
Group
Value
95% CI
Treatment
3.9
± 1.8
YF476 Placebo
8.8
± 3.7
Week 6
Group
Value
95% CI
Treatment
1.8
± 0.9
YF476 Placebo
16.9
± 9.8
Week 8
Group
Value
95% CI
Treatment
3.8
± 1.8
YF476 Placebo
10.9
± 6.0
Week 12
Group
Value
95% CI
Treatment
2.9
± 2.5
YF476 Placebo
10.6
± 7.4
Follow-up
Group
Value
95% CI
Treatment
19.8
± 26.1
YF476 Placebo
11.9
± 7.2
Adverse events — posted to ClinicalTrials.gov
Time frame: 16 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Trio Medicines Ltd.
Last refreshed: 12 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02597712.